BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37167718)

  • 1. Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells.
    Kim MS; Yang SH; Kim MS
    Biochem Biophys Res Commun; 2023 Jul; 666():1-9. PubMed ID: 37167718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRPML3 enhances drug resistance in non-small cell lung cancer cells by promoting Ca
    Kim MS; Yang SH; Kim MS
    Biochem Biophys Res Commun; 2022 Oct; 627():152-159. PubMed ID: 36037747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
    Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
    J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
    Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia.
    Efferth T; Gillet JP; Sauerbrey A; Zintl F; Bertholet V; de Longueville F; Remacle J; Steinbach D
    Mol Cancer Ther; 2006 Aug; 5(8):1986-94. PubMed ID: 16928819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines.
    Noutomi T; Chiba H; Itoh M; Toyota H; Mizuguchi J
    Oral Oncol; 2002 Jan; 38(1):41-8. PubMed ID: 11755820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds.
    Mack JT; Townsend DM; Beljanski V; Tew KD
    Curr Drug Metab; 2007 Jan; 8(1):47-57. PubMed ID: 17266523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hedgehog signaling promotes multidrug resistance by regulation of ABC transporters in oral squamous cell carcinoma.
    Lu X; Wang Z; Huang H; Wang H
    J Oral Pathol Med; 2020 Oct; 49(9):897-906. PubMed ID: 32512620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
    Yanase K; Tsukahara S; Mitsuhashi J; Sugimoto Y
    Cancer Lett; 2006 Mar; 234(1):73-80. PubMed ID: 16303243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
    Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
    Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.
    He S; Shi J; Zhou H; Li Q; Wu L
    Cancer Gene Ther; 2022 Nov; 29(11):1686-1696. PubMed ID: 35701616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ATP-binding cassette transporter ABCA2 as a mediator of intracellular trafficking.
    Mack JT; Beljanski V; Tew KD; Townsend DM
    Biomed Pharmacother; 2006 Nov; 60(9):587-92. PubMed ID: 17029687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
    Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.